Wall Street analysts forecast that Scpharmaceuticals Inc (NASDAQ:SCPH) will post ($0.54) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Scpharmaceuticals’ earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.53). Scpharmaceuticals reported earnings of ($0.39) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 38.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, August 5th.
On average, analysts expect that Scpharmaceuticals will report full-year earnings of ($1.80) per share for the current fiscal year, with EPS estimates ranging from ($1.95) to ($1.54). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.95) per share, with EPS estimates ranging from ($2.17) to ($1.69). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.19.
A number of equities research analysts have recently weighed in on SCPH shares. HC Wainwright restated a “buy” rating and set a $15.00 target price (up previously from $13.00) on shares of Scpharmaceuticals in a research report on Wednesday, May 13th. BMO Capital Markets reiterated a “market perform” rating and issued a $14.00 price objective on shares of Scpharmaceuticals in a report on Tuesday, June 23rd. ValuEngine upgraded Scpharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. SVB Leerink dropped their price objective on Scpharmaceuticals from $12.00 to $10.00 and set a “market perform” rating for the company in a report on Wednesday, May 27th. Finally, Zacks Investment Research upgraded Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a report on Tuesday, March 31st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $11.88.
In other news, major shareholder Andrew J. Schwab acquired 578,034 shares of Scpharmaceuticals stock in a transaction dated Tuesday, May 26th. The stock was bought at an average cost of $8.65 per share, with a total value of $4,999,994.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.07% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of SCPH. Renaissance Technologies LLC increased its stake in shares of Scpharmaceuticals by 46.0% during the fourth quarter. Renaissance Technologies LLC now owns 163,677 shares of the company’s stock worth $926,000 after purchasing an additional 51,546 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Scpharmaceuticals by 21.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 17,791 shares of the company’s stock worth $101,000 after purchasing an additional 3,157 shares during the period. Matisse Capital increased its stake in shares of Scpharmaceuticals by 88.5% during the first quarter. Matisse Capital now owns 27,685 shares of the company’s stock worth $205,000 after purchasing an additional 13,000 shares during the period. Trexquant Investment LP bought a new position in shares of Scpharmaceuticals during the first quarter worth approximately $123,000. Finally, Acadian Asset Management LLC increased its stake in Scpharmaceuticals by 16.5% during the 1st quarter. Acadian Asset Management LLC now owns 10,347 shares of the company’s stock worth $76,000 after acquiring an additional 1,463 shares during the period. 59.44% of the stock is owned by hedge funds and other institutional investors.
Shares of SCPH stock traded down $0.34 on Tuesday, reaching $7.36. 84,434 shares of the stock were exchanged, compared to its average volume of 106,407. The stock has a market cap of $151.27 million, a PE ratio of -4.46 and a beta of 0.50. Scpharmaceuticals has a one year low of $3.21 and a one year high of $11.99. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.96 and a quick ratio of 16.96. The stock has a 50 day moving average price of $8.46 and a 200 day moving average price of $7.67.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
See Also: What is a stock portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.